Partnering with us
 |
Partnering with the best early stage science and clinical-stage programs is our top priority. We are dedicated to building strong partnership with top-tier research institutes, biotech and pharmaceutical companies. Our initial focus is to partner with assets with potential synergy with our current portfolio to enable us to select the winning combination and deliver meaningful benefit in the fight against cancer. BD related business please contact Email:BD@inxmed.com |
Ifebemtinib
Ifebemtinib (also known as IN10018, ifebe, BI853520) is an orally administered, highly potent and selective small molecular inhibitor of the focal adhesion kinase (FAK). InxMed translational research has demonstrated the essential functions of FAK in tumor defense.
OMTX705
OMTX705 is an ADC formed by a new humanized anti-FAP mAb that has been conjugated to a novel cytolysin, TAM470, a synthetic microtubule inhibitor from the tubulysin family. IN30705 is designed to target FAP-expressing Cancer Associated Fibroblasts (CAFs) in tumor microenvironment.
NEXT GENERATION ADC
InxMed has developed ADC to address with aims of stronger, more potent ADC to overcome emerging resistance and companion biomarker test sparing.
We invent personalized medicines with global impact, and turn innovation in China to life saving therapies for the world
QUICK LINKS
CONTACT US
Tel: +86 25-58251030
Email: office@inxmed.com
Office address: 73 Tanmi Road Block D-2, 3rd Floor Jiangbei New District, Nanjing
MESSAGE
Follow Us：
CopyRight © 2022 InxMed All Rights Reserved.